Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12928-023-00951-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemodynamic effect of supra-annular implantation of SAPIEN 3 balloon expandable valve.
Cardiovasc Interv Ther
September 2024
Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine, OSAKA, Japan.
The hemodynamic impact of the implantation depth for balloon-expandable valves is under-investigated, especially with higher implantation techniques. We assessed the hemodynamic performance of supra-annular SAPIEN 3 valve implantation. This retrospective study involved consecutive patients who underwent transcatheter aortic valve replacement (TAVR) using the SAPIEN 3.
View Article and Find Full Text PDFSevere intraprosthetic aortic insufficiency immediately after implantation of a SAPIEN 3 Ultra RESILIA valve with spontaneous resolution: case report.
Eur Heart J Case Rep
August 2024
Cardiovascular Medicine, Asia Medical Group, Sapporo Heart Center, Sapporo Cardio Vascular Clinic, North 49, East 16, 8-1, Higashi Ward, Sapporo 007-0849, Japan.
Background: Aortic insufficiency (AI) is often encountered in transcatheter aortic valve replacement (TAVR) but is only rarely haemodynamically significant. Even more uncommon is the occurrence of intraprosthetic AI that often leads to haemodynamic compromise requiring additional therapeutic intervention.
Case Summary: An 85-year-old female with severe aortic stenosis underwent elective TAVR with a size 23 mm SAPIEN 3 Ultra RESILIA (S3UR) valve.
Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis.
JACC Cardiovasc Interv
April 2024
Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Article Synopsis
- The study compares the 5-year rates of valve reintervention after transcatheter aortic valve replacement (TAVR) using CoreValve/Evolut versus surgical aortic valve replacement (SAVR).
- It found that TAVR had a higher overall reintervention rate (2.2%) compared to SAVR (1.5%), particularly within the first year.
- Evolut TAVR showed significantly fewer reinterventions than CoreValve TAVR, but its rates were comparable to SAVR, indicating varying risks associated with different valve types.
TAV-in-TAV for paravalvular aortic regurgitation due to a deeply implanted Navitor transcatheter aortic valve.
Cardiovasc Interv Ther
January 2024
Department of Cardiology, Sapporo Higashi Tokushukai Hospital, 3-1, Kita 33-Jo Higashi 14-Chome, Higashi-Ku, Sapporo, 065-0033, Japan.
Transcatheter aortic valve-in-valve implantation to treat aortic para-valvular regurgitation after TAVI.
Int J Cardiol
October 2022
Background: Para-valvular regurgitation (PVR) after transcatheter aortic valve (TAV) implantation is associated with increased mortality. Redo-TAVI may be applied to treat PVR, yet with unknown efficacy. We thought to assess redo-TAVI efficacy in reducing PVR using the Redo-TAVI registry (45 centers; 600 TAV-in-TAV cases).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!